METAB-HTX is a prospective, longitudinal cohort study evaluating cardiac and systemic metabolism in heart transplant recipients.
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
diastolic and systolic left ventricular function
Timeframe: Baseline, 1 year, and 2 years after heart transplantation
CAV diagnosis
Timeframe: Baseline, 1 year, and up to 24 months
Allograft rejection will be evaluated by endomyocardial biopsy
Timeframe: 1 year and 5 years after heart transplantation
Worsening of kidney function
Timeframe: Baseline, 1 year, and 2 years after heart transplantation
Infection requiring heath care professional interventions
Timeframe: Baseline, 1 year, and 2 years after heart transplantation
Diagnosis of malignencies
Timeframe: Baseline, 1 year, and 2 years after heart transplantation
Worsening of metabolic derangements
Timeframe: Baseline, 1 year, and 2 years after heart transplantation
Liver deterioration
Timeframe: Baseline, 1 year, and 2 years after heart transplantation